ライフサイエンスコーパス: RSV

1 RSV alone reduced nicotinamide adenine dinucleotide phos

2 RSV B (all BA9 genotype) predominated over RSV A (all ON

3 RSV F protein nanoparticle vaccination in pregnant women

4 RSV infection in hospitalized older adults often manifes

5 RSV infection was confirmed by RT-qPCR with any positive

6 RSV reduced the progression of EP and the levels of NADP

7 RSV significantly inhibited the development of periodont

8 RSV targets ciliated epithelial cells in the airways, bu

9 RSV was also associated with 25.0-37.5% of deaths from m

10 RSV-induced epithelial cell death was associated with in

11 RSV-seronegative children aged 6-24 months received 1 in

12 2:1) at 106 plaque-forming units (PFU) in 15 RSV-seropositive children and at 105 and 106 PFU in 21 a

13 a correlate of susceptibility/severity; (2) RSV-specific CD8+ T cells in bronchoalveolar lavage flui

14 children and at 105 and 106 PFU in 21 and 30 RSV-seronegative children, respectively.

15 ature (n = 4446), and full-term (n = 33 417) RSV-infected infants were matched to 424, 791, 8875, and

16 overing the management of a total of 365 828 RSV disease episodes.

17 A study of respiratory syncytial virus-A (RSV A) genotype ON1 genetic variability and clinical sev

18 ed to that for wild-type RSV, the r2stop+A4G RSV was better able to infect BALB/c mice in the presenc

19 Notably, while rA4G and r2stop+A4G RSV were attenuated in cells and in naive BALB/c mice co

20 Maternally acquired RSV antibodies were associated with protection of infant

21 Ad26.RSV.preF (LD and HD) had an acceptable safety profile an

22 evaluated the experimental RSV vaccine, Ad26.RSV.preF, a replication-incompetent adenovirus 26 vector

23 med on 3-wk- (juvenile) and 8-wk-old (adult) RSV-infected C57BL/6 mice to investigate age-related dif

24 rature, humidity and wind speed in affecting RSV transmission that could be biological or could refle

25 % of those occurring 1 week to 1 month after RSV illness (80.3%; 28.5%-94.6%).

26 ified success criterion for efficacy against RSV-associated, medically significant lower respiratory

27 and only one prophylactic treatment against RSV, palivizumab, for high-risk infants.

28 evaluated an investigational vaccine against RSV (ChAd155-RSV) using the viral vector chimpanzee-aden

29 epitope changes in RSV A isolates, while all RSV B isolates had 2-amino acid substitution in the supt

30 irculatory deaths in the first year after an RSV episode.

31 ed risk of death in the first month after an RSV illness episode leading to healthcare attendance.

32 ever, it has been a challenge to identify an RSV vaccine strain that has an optimal balance between a

33 d healthy had significantly higher RSV-A and RSV-B titers compared to infants that subsequently contr

34 es, adapted to the changing demographics and RSV seasonality of a low-income country.

35 esent the ectodomains of influenza, HIV, and RSV viral glycoprotein trimers.

36 well as the paramyxoviruses PIV5, HPIV3, and RSV.

37 , reactogenicity, RSV-antibody responses and RSV-associated medically attended acute respiratory illn

38 ot, functional neutralizing antibodies, anti RSV-F immunoglobin (Ig) G, and ChAd155 neutralizing anti

39 Serum RSV-neutralizing antibodies and anti-RSV fusion immunoglobulin G increased >=4-fold in 95% an

40 ease severity in adults were: (1) lower anti-RSV neutralizing antibodies, where neutralizing antibody

41 ells in the airways, but how viruses such as RSV interact with receptors on these cells is not unders

42 The incidence of medically attended RSV-associated lower respiratory tract infection was 70.

43 A live attenuated RSV vaccine is one of the most promising vaccine strateg

44 Inhibition of RIPK1 or MLKL attenuated RSV-induced HMGB1 translocation and release, and lowered

45 BinaxNOW RSV should be used and interpreted with caution.

46 Both RSV and flu outbreaks were associated with surges in MAA

47 We simulate future trajectories of both RSV and influenza, using an epidemic model.

48 lize the RSV N protein and p65 within bovine RSV (bRSV) IBs, which are granular, membraneless regions

49 cells were the target for both viruses, but RSV apical release was significantly more efficient than

50 ological immaturity and immunosuppression by RSV-specific maternal antibodies.

51 Reducing the viral load by RSV antivirals might provide substantial benefits to out

52 In addition, reduced IFNgamma secretion by RSV-induced T cells in older vaccinees correlates with l

53 ized by two disulfide bonds, but it captures RSV G in a conformation not previously observed, reveali

54 Compared to RSV-negative ARI cases, RSV-positive cases were associated with cough, apnoea an

55 eron gamma-secreting T-cells after a ChAd155-RSV high dose was 108.3/106 PBMCs at D30, with no increa

56 investigational vaccine against RSV (ChAd155-RSV) using the viral vector chimpanzee-adenovirus-155, e

57 2stop+A4G genotype in currently circulating RSV-A strains.IMPORTANCE Strain-specific differences in

58 Genetic variation in circulating RSV strains will continue to challenge prevention effort

59 all adult ages during RSV, flu, and combined RSV-flu outbreak periods compared to nonoutbreak periods

60 st in adults aged >=65 years during combined RSV-flu outbreak periods.

61 .04 to 1.38 during the RSV, flu, or combined RSV-flu outbreaks compared to the nonoutbreak periods, w

62 We compare RSV-associated admission rates, age, seasonality, and ti

63 ldren with a history of laboratory-confirmed RSV infection.

64 ared to infants that subsequently contracted RSV.

65 mum wind speed was correlated with decreased RSV transmissibility.

66 evention and used this information to define RSV and flu outbreak periods in the Maryland area.

67 rmation not observed in previously described RSV G-antibody structures.

68 dase) levels, in comparison to DM+INS and DM+RSV+INS (P < 0.05).

69 re lower in PLAC when compared to DM+RSV, DM+RSV+INS and NDM (P < 0.05).

70 evels were lower in PLAC when compared to DM+RSV, DM+RSV+INS and NDM (P < 0.05).

71 Inhibition of either UA or IL-1beta during RSV infection led to chronic reductions in pulmonary imm

72 receptor antagonist was administered during RSV infection.

73 nsistently greater for all adult ages during RSV, flu, and combined RSV-flu outbreak periods compared

74 stration of the chemoattractant CXCL1 during RSV infection affected disease severity as measured by w

75 versican promotes airway inflammation during RSV infection further demonstrating that versican's role

76 ors contribute to airway inflammation during RSV infection remains unknown.

77 pment of AHR and airway inflammation, during RSV infection.

78 ciated with the inflammatory response during RSV infection (i.e., CCL-2, CCL-3, CCL-5, IL-6) as well

79 We use a dynamic RSV transmission model which captures transmission both

80 Prevention of early RSV will require passive protection via maternal immuniz

81 development and implementation of effective RSV prevention and treatment measures represent an oppor

82 To assess antiviral effects, RSV RNA viral load from nasal swabs was quantified over

83 l vector chimpanzee-adenovirus-155, encoding RSV fusion (F), nucleocapsid, and transcription antiterm

84 al population dynamics of a globally endemic RSV genotype within a discrete location.

85 g developed to protect infants for an entire RSV season with a single intramuscular dose.

86 o better understand differences in estimated RSV burden across study design.

87 We examined RSV and influenza (flu) surveillance data from the US Na

88 We evaluated the experimental RSV vaccine, Ad26.RSV.preF, a replication-incompetent ad

89 l efficacy in participants with experimental RSV infection.

90 Registries provide opportunities to explore RSV epidemiology and burden.

91 parainfluenza virus (PIV) vector expressing RSV fusion protein engineered for enhanced immunogenicit

92 uction of versican was not altered following RSV infection; however, BEC production of versican was s

93 an was significantly downregulated following RSV infection.

94 r matrix accumulation of HA occurs following RSV infection and may contribute to airway inflammation.

95 ote an altered Th2 immune response following RSV infection that leads to more severe immunopathology.

96 sociated with respiratory sequelae following RSV infection and characterizing the viral load, RSV who

97 During the following RSV season, medically attended acute respiratory illness

98 and antibody responses during the following RSV season.

99 ity was 2.2/1000 (95% CI, 0.7-3.7/1000); for RSV, the rate was 0.8/1000 (95% CI, 0-1.7/1000) with a c

100 evidence of possible causal attribution for RSV (OR, 8.5 [95% CI, 3.9-18.5]; AFE, 88%), Flu (OR, 8.3

101 lene glycol-conjugated catalase (PG-CAT) for RSV-infected mice.

102 , a respiratory sample will be collected for RSV molecular diagnosis.

103 Nucleolin is an entry coreceptor for RSV(2) and also mediates the cellular entry of influenza

104 no vaccine or effective treatment exists for RSV.

105 months of life and identify risk factors for RSV infection and progression to severe disease.

106 y efficacy end point was hospitalization for RSV-associated lower respiratory tract infection through

107 01) and the incidence of hospitalization for RSV-associated lower respiratory tract infection was 78.

108 of the most promising vaccine strategies for RSV.

109 ILC2-derived IL-13 was sufficient for RSV-driven AHR, since reconstitution of wild-type ILC2 r

110 10% (n = 45 699) of children were tested for RSV and 16% (n = 11 461) of these tested positive.

111 Human tracheal aspirates from RSV-infected infants showed elevated pro-IL-1beta mRNA a

112 well as pulmonary dendritic cells (DC) from RSV-infected mice upregulated the expression of Kdm6b/Jm

113 o reduce severe morbidity and mortality from RSV in this age group.

114 or nucleocapsid-like particles (NCLPs) from RSV and other nonsegmented negative-sense RNA viruses ha

115 so recovered more apoptotic neutrophils from RSV-infected cultures (>40%) than from mock-infected cul

116 ese data suggest a potential value of future RSV vaccination programs on subsequent respiratory healt

117 oration with an international working group (RSV GEN) and claim databases.

118 ho remained healthy had significantly higher RSV-A and RSV-B titers compared to infants that subseque

119 replication and induced significantly higher RSV-PRNTs than RSV.

120 Boosting instead with the rB/HPIV3-RSV-pre-F vectors resulted in efficient replication and

121 edically attended acute respiratory illness (RSV-MAARI) and antibody responses during the following R

122 In RSV- or HMPV-infected cells, cytosolic inclusion bodies

123 In RSV-infected infants, JNJ-8678 was well tolerated.

124 In RSV-seronegative children, the 105 PFU dose was overatte

125 The role of IL-33/ILC2 axis in RSV-induced AHR inflammation and eosinophilia were evalu

126 including ILC2s and ST2(+) myeloid cells, in RSV infection-triggered pathophysiology.

127 emonstrated no suptavumab epitope changes in RSV A isolates, while all RSV B isolates had 2-amino aci

128 the RSV polymerase protein was evaluated in RSV-seronegative children.

129 pendently associated with hospitalization in RSV-positive children.

130 to D30) in anti-F IgG over the fold-rise in RSV-A-neutralizing antibodies was 1.01.

131 tive humidity were associated with increased RSV transmissibility, while higher value of maximum wind

132 determine factors associated with increased RSV-ARI severity in young children.

133 Infant RSV infection has a significant long-term healthcare-res

134 Maternal and infant RSV titers were strongly correlated.

135 106 PFU dose was well tolerated, infectious (RSV/DeltaNS2/Delta1313/I1314L replication detected in 90

136 Study type influenced RSV-associated hospitalization rates (P=.003), with acti

137 Live RSV vaccine D46/NS2/N/DeltaM2-2-HindIII, attenuated by d

138 infection and characterizing the viral load, RSV whole-genome sequencing, host immune response, and t

139 By contrast, unmyristoylated HIV-1 MA, RSV MA, and a PH domain all preferred to interact with f

140 Future maternal RSV vaccines may have added benefit in high HIV prevalen

141 Median RSV viral load change from baseline in JNJ-8678 vs place

142 ion of UA or IL-1beta during neonatal murine RSV infection decreased mucus production, reduced cellul

143 rimed for anamnestic responses after natural RSV exposure.

144 Interestingly, neither RSV nor HMPV formed syncytia in HAE tissues.

145 Validated biomarkers of RSV disease severity would benefit diagnostics, treatmen

146 allenge studies in volunteers, biomarkers of RSV susceptibility or disease severity in adults were: (

147 t of maternal HIV infection on the burden of RSV among mothers and their infants in western Kenya.

148 Here, we compare the burden of RSV hospitalizations (RSVH) and all-cause bronchiolitis

149 The disease burden of RSV-ARI among older adults is substantial, with limited

150 orldwide investigating the disease burden of RSV-ARI in this population.

151 d data to explore epidemiology and burden of RSV.

152 infants against community-detected cases of RSV-ILI and pneumonia.

153 Unpublished data on the management cost of RSV episodes were collected through collaboration with a

154 ccine, LID/DeltaM2-2/1030s, with deletion of RSV ribonucleic acid synthesis regulatory protein M2-2 a

155 Early detection of RSV can optimize clinical management and minimize use of

156 itivity of BN for point-of-care detection of RSV infection.

157 xamined and nasal swabs for the detection of RSV were obtained during each respiratory illness.

158 :1 to receive a single intramuscular dose of RSV fusion (F) protein nanoparticle vaccine or placebo.

159 A single intranasal dose of RSV/DeltaNS2/Delta1313/I1314L was evaluated in a double-

160 Age-stratified estimates of RSV burden are urgently needed for vaccine implementatio

161 This study provides the first estimates of RSV incidence in Mali.

162 ified 25 studies with 31 unique estimates of RSV-associated hospitalization rates.

163 ortant for cost-effectiveness evaluations of RSV interventions in planned or ongoing trials.

164 CCL5 in the bronchoalveolar lavage fluid of RSV-infected mice, without increasing viral replication

165 The median frequency of RSV-F-specific interferon gamma-secreting T-cells after

166 nd in-hospital case-fatality ratio (hCFR) of RSV-ARI in older adults, stratified by industrialized an

167 The incidence of RSV pneumonia was 29 cases per 1000 person-years.

168 luenza vaccination, we estimate incidence of RSV-associated febrile illness in the first 6 months of

169 The incidence of RSV-associated hospitalizations was 45.6 per 1000 person

170 patient and outpatient cost of management of RSV-ALRI in young children to assist health policy maker

171 eak viral load or clinical manifestations of RSV disease.

172 rying efficacy in a human challenge model of RSV disease.

173 , we found that the flexible hinge region of RSV L protein is tolerant to amino acid deletion or inse

174 We examined relationships of RSV and flu outbreaks to occurrence of 4 advanced medica

175 However, the role of RSV genotypes in human infection is incompletely underst

176 Therefore, we aimed to evaluate the role of RSV in ARI disease severity and determine factors associ

177 etermining susceptibility to and severity of RSV disease in adults have not been well defined.

178 ab effectively inhibited entry and spread of RSV in HAE tissues, with nirsevimab displaying significa

179 ause of a newly circulating mutant strain of RSV B.

180 y, as well as significantly higher titers of RSV-specific mucosal IgA antibodies.

181 ctors induced 7- to 15-fold higher titers of RSV-specific serum antibodies with high neutralizing act

182 that we describe enable precise tracking of RSV-specific CD4+ cells, potentially accelerating the de

183 p a birth cohort to obtain incidence data on RSV acute respiratory tract infection (ARTI).

184 nd EMBASE for studies reporting cost data on RSV management in children under 60 months from 2000 to

185 nducted a meta-analysis of available data on RSV-associated ALRI hospitalizations in children aged <5

186 proliferative factors that have no effect on RSV attachment but reduce RSV replication in a minigenom

187 A pre-formulation study on RSV-loaded niosomes was carried out to determine the mos

188 ith any positive value (ITT-I population) or RSV RNA >=1 log10PFUe/mL (ITT-IS population) in nasal wa

189 RSV B (all BA9 genotype) predominated over RSV A (all ON1 genotype) globally (69.0% versus 31.0%) a

190 Suptavumab did not reduce overall RSV hospitalizations or outpatient LRTI because of a new

191 l during January 2013-May 2017 with positive RSV polymerase chain reaction respiratory specimens was

192 an important proxy for determining potential RSV vaccination strategies.

193 tro de novo RNA synthesis using the purified RSV polymerase as 8 nucleotides (nt), shorter than previ

194 e presence of preexisting immunity than rA4G RSV.

195 Infection with the recombinant A4G (rA4G) RSV mutant resulted in transcriptional readthrough and l

196 itored for vaccine shedding, reactogenicity, RSV-antibody responses and RSV-associated medically atte

197 e of these RSV G gene mutations, recombinant RSV strains harboring either a wild-type A2 strain G gen

198 have no effect on RSV attachment but reduce RSV replication in a minigenome assay.

199 susceptibility, and 16 substitutions reduced RSV susceptibility to presatovir (2.9- to 410-fold).

200 nce reconstitution of wild-type ILC2 rescued RSV-driven AHR in IL-13-deficient mice.

201 Emergence of presatovir-resistant RSV occurred during therapy but did not significantly af

202 Over the RSV season, RSV-MAARI occurred in 2 vaccinees and 4 placebo recipien

203 Sequenced RSV isolates demonstrated no suptavumab epitope changes

204 Serum RSV-neutralizing antibodies and anti-RSV fusion immunogl

205 but induced a significant increase in serum RSV-neutralizing antibodies.

206 nees), and immunogenic (geometric mean serum RSV plaque-reduction neutralizing antibody titer, 1:64).

207 While the serum RSV G antibody repertoires in the 2 groups were similar,

208 spiratory syncytial virus (RSV), and several RSV vaccines and monoclonal antibodies currently in clin

209 e are known clinical risk factors for severe RSV infection, the majority of those hospitalized are pr

210 bjective is to identify biomarkers of severe RSV acute respiratory tract infection (ARTI) in infants.

211 The risk of severe RSV-ALRI (odds ratio, 2.2; 95% confidence interval [CI],

212 ly-transferred antibodies can prevent severe RSV illness, and maternal immunization may reduce illnes

213 ted into the airways of children with severe RSV disease.

214 ocal immune responses associated with severe RSV in infants.

215 Increased recognition of the substantial RSV disease burden in adults will be important in evalua

216 Surprisingly, RSV G complexed with 3G12 adopts a distinct conformation

217 xposure was highly predictive of symptomatic RSV disease.

218 induced significantly higher RSV-PRNTs than RSV.

219 n human airway epithelial (HAE) tissues than RSV, suggesting HMPV may promote cell-to-cell spread via

220 ice [SPC-Cre(+) Vcan(-/-)] demonstrated that RSV infection led to increased HA accumulation compared

221 We found that RSV notably inhibited the TNF-alpha-induced osteoclast f

222 To test the hypothesis that RSV infection promotes inflammation via altered HA and v

223 Taken together, our study indicates that RSV prevents the exacerbation of atherosclerosis induced

224 In this study, we show that RSV-infected bone marrow-derived dendritic cells (BMDC)

225 ically relevant model system, we showed that RSV infects and spreads more efficiently than HMPV, with

226 The RSV boost was highly restricted but induced a significan

227 The RSV burden was higher when stratified by inpatient and o

228 ory deaths occurring within 1 week after the RSV episode were attributable to RSV (attributable fract

229 After the RSV season, 9 of 20 vaccinees had increases in the RSV t

230 electron microscopy (CLEM) to colocalize the RSV N protein and p65 within bovine RSV (bRSV) IBs, whic

231 outcomes ranged from 1.04 to 1.38 during the RSV, flu, or combined RSV-flu outbreaks compared to the

232 emperature-sensitivity mutation 1030s in the RSV polymerase protein was evaluated in RSV-seronegative

233 ason, 9 of 20 vaccinees had increases in the RSV titer that were significantly greater than those in

234 rs, and the evolutionary implications of the RSV polymerase.

235 aM2-2-HindIII, attenuated by deletion of the RSV RNA regulatory protein M2-2, is based on previous ca

236 expected delivery date near the start of the RSV season, were randomly assigned in an overall ratio o

237 or placebo (484 infants) at the start of the RSV season.

238 dy, we describe the crystal structure of the RSV surface glycoprotein G in complex with a broadly neu

239 Over the RSV season, RSV-MAARI occurred in 2 vaccinees and 4 plac

240 Antibodies targeting the RSV G central conserved domain are protective in both pr

241 parison to other structures reveals that the RSV G central conserved domain is flexible and can adopt

242 To investigate the biological role of these RSV G gene mutations, recombinant RSV strains harboring

243 a significantly higher antibody affinity to RSV G was observed in nasal washes from early-recovered

244 k after the RSV episode were attributable to RSV (attributable fraction, 93.9%; 95% confidence interv

245 The antibody binds to RSV G at a highly conserved region stabilized by two dis

246 Compared to RSV-negative ARI cases, RSV-positive cases were associat

247 ated the number of in-hospital deaths due to RSV-ARI by combining hCFR data with hospital admission e

248 ysiological concentrations of neutrophils to RSV-infected nasal cultures was associated with greater

249 expression of NbP3IP conferred resistance to RSV infection in Nicotiana benthamiana.

250 oost strategy.IMPORTANCE Immune responses to RSV in infants can be reduced due to immunological immat

251 extraction for the analysis of Mel and trans-RSV in wines by LC-FLD was developed.

252 e BALB/c mice compared to that for wild-type RSV, the r2stop+A4G RSV was better able to infect BALB/c

253 During follow-up, RSV-infected cohorts had higher average all-cause cumula

254 ic avian alpharetrovirus Rous sarcoma virus (RSV) Gag protein undergoes transient nucleocytoplasmic t

255 ressor protein encoded by Rice stripe virus (RSV), a negative-strand RNA virus.

256 luB) virus, and respiratory syncytial virus (RSV) (FFABR assay).

257 e the burden of respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) LRTI in premature

258 tes of America: respiratory syncytial virus (RSV) and seasonal influenza.

259 s the long-term respiratory syncytial virus (RSV) burden among preterm and full-term infants in the U

260 enicity of live respiratory syncytial virus (RSV) candidate vaccine, LID/DeltaM2-2/1030s, with deleti

261 ease.IMPORTANCE Respiratory syncytial virus (RSV) causes severe respiratory infections in infants, yo

262 Respiratory syncytial virus (RSV) disease is a major cause of infant morbidity and mo

263 hibitors of the respiratory syncytial virus (RSV) fusion protein block entry of the virus into the ce

264 Respiratory syncytial virus (RSV) infection causes significant morbidity in hematopoi

265 Respiratory syncytial virus (RSV) infection in mouse and human lung is associated wit

266 Respiratory syncytial virus (RSV) infection is epidemiologically linked to asthma.

267 Respiratory syncytial virus (RSV) is a leading cause of viral pneumonia and bronchiol

268 Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory infecti

269 Respiratory syncytial virus (RSV) is a nonsegmented negative-sense (NNS) RNA virus an

270 Respiratory syncytial virus (RSV) is a top cause of severe lower respiratory tract di

271 Respiratory syncytial virus (RSV) is recognised as a leading cause of severe acute re

272 Respiratory syncytial virus (RSV) is the leading global cause of severe pediatric acu

273 Human respiratory syncytial virus (RSV) is the leading viral cause of lower respiratory tra

274 Respiratory syncytial virus (RSV) is the most common viral pathogen associated with a

275 Respiratory syncytial virus (RSV) is the primary cause of respiratory tract infection

276 differences in respiratory syncytial virus (RSV) isolates are associated with differential pathogene

277 We administered respiratory syncytial virus (RSV) to 58 volunteers, of whom 57% became infected.

278 n the genome of respiratory syncytial virus (RSV) to codon pair optimization (CPO) by increasing the

279 Respiratory syncytial virus (RSV) typically causes winter outbreaks in temperate clim

280 n the genome of respiratory syncytial virus (RSV) were codon pair optimized (CPO) by increasing the c

281 litis caused by respiratory syncytial virus (RSV), and several RSV vaccines and monoclonal antibodies

282 common viruses: respiratory syncytial virus (RSV), influenza virus (Flu), parainfluenza virus (PIV),

283 in infants with respiratory syncytial virus (RSV)-induced lower respiratory tract infections.

284 biome(Haemophilus)T2(low); endotype C, virus(RSV/RV)microbiome(Streptococcus)T2(low); and endotype D,

285 omoter sequence as essential to the in vitro RSV polymerase activity, consistent with the results pre

286 or moderate (maintained in the general ward) RSV disease at 5 to 9 days after enrollment.

287 al and regional burdens in older adults with RSV-ARI in the community and in hospitals for that year.

288 ic and epigenetic signatures associated with RSV disease severity.

289 R], 16.5; 95% CI, 13.7-19.8) associated with RSV-ALRI was higher among children with underlying CHD a

290 fection with RSV and were given a boost with RSV or a parainfluenza virus (PIV) vector expressing RSV

291 ected BMDCs exacerbate a live challenge with RSV infection but was inhibited when BMDCs were treated

292 At least one third of children with RSV infection presenting to ED were diagnosed as other i

293 Compared with RSV, boosts with the vectors induced 7- to 15-fold highe

294 There were 664 patients hospitalized with RSV (61% female, 64% aged >=75 years).

295 Among infants with RSV illness, males were more likely to be hospitalized.

296 rity were noted among children infected with RSV A and B.

297 received a primary intranasal infection with RSV and were given a boost with RSV or a parainfluenza v

298 AECs and neonatal mice were inoculated with RSV and murine Pneumovirus, respectively.

299 Airway sensitization of naive mice with RSV-infected BMDCs exacerbate a live challenge with RSV

300 chment of epithelial cells than is seen with RSV infection alone.

301 N-lambda airway secretion; (b) subjects with RSV infection showed the highest IFN-lambda airway level